Create

Sign in to ReadmeX

or

How we handle your data: Privacy Policy

ReadmeX

Your AI reading companion

What would you like to catch up on?

Pick a briefing, or ask your own question.

Your community and people briefings stay personal to you.

Novartis

AI overview

Sign in and the AI will write an overview from our coverage.

Headlines · 6

  1. Seven drugmakers report AI gains in early drug discovery

    According to the report, senior researchers from seven major pharmaceutical companies said AI has accelerated early drug development, with some time savings reported at up to half. Novo Nordisk said AI reduced iterations for designing, producing and testing new molecules from about eight to three, while Novartis said the average time from project launch to candidate selection fell from three years to about 18 months to two years. Sanofi said an AI-assisted approach allowed it to skip a dose-selection study and advance the asthma candidate lunsekimig by at least a year. These are company-reported results; the report says whether AI improves clinical-development success or approval rates remains unverified.

    虎嗅 AI · 🔥 5
  2. Novartis CEO Says AI Could Shorten Drug Development to Eight Years

    Novartis CEO Vasant Narasimhan told Bloomberg that AI could cut drug-development time from 12 years to eight and significantly improve the odds of bringing medicines to market. He said AI is already helping Novartis speed up clinical trials, analyze data and identify new drug candidates.

    Bloomberg Technology · 🔥 4
  3. Isomorphic Labs President Predicts AI Will Design All Drugs

    Isomorphic Labs President Max Jaderberg said he expects AI eventually to design all drugs, while acknowledging that the timing is uncertain. The company remains in preclinical development and plans to begin its first clinical trial by the end of 2026 to test AI-designed candidates in patients. Its IsoDDE drug-design engine is supported by company-published technical results that have not yet been independently validated.

    MIT科技评论中文 · 🔥 0
  4. Commentary: AI Agents Still Rely on Human Labor

    TMTPost commentary argues that companies often use AI and increased compute as a rationale for reducing headcount, while presenting the move as operational efficiency. It cites Dazzle AI, Duckbill and Wajo AI as using contractors for real-world steps agents cannot reliably handle, and reports that human call-center staff assisted Meta's Muse during early testing. The article distinguishes human-AI collaboration from replacing employees before agents can handle exceptions, but many vendor and market claims are not independently verified in the supplied report.

    钛媒体 · 🔥 0
  5. AI is not a cure for bad management

    36Kr 人工智能 argues that AI can improve efficiency but cannot replace human judgment, organizational coordination, or responsibility for complex and exceptional cases. It cites current AI agents that hand off real-world tasks to contractors, along with market concerns about heavy AI spending and weaker investor enthusiasm. The commentary also argues that layoffs marketed as AI-driven cost savings often shift labor costs to less stable outsourced work.

    36氪 人工智能 · 🔥 0
  6. Companies Report Early Financial Gains From AI

    Santander, Novartis and other companies say AI is beginning to boost revenue, cut costs or improve profitability as investors seek returns. These are company-reported claims about the early financial effects of AI adoption, and the supplied report provides no figures or independent verification.

    CNBC Technology · 🔥 0

Experience and discussion from the community

Share my Novartis experienceAsk about Novartis

Nobody has shared their experience with Novartis yet.